17 unknown, 15 recruiting, 13 completed, 4 active not recruiting. 32 Phase 1, 27 Phase 2, 11 Phase 3, 1 Not applicable.
Follow Mabwell (Shanghai) Bioscience Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy 7MW3711, Docetaxel - Lung Squamous Cell Carcinoma | Phase 3 | Not yet recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 600 | 2026-10-01 | 2026-09-21 |
| A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer 9MW2821, Chemotherapy - Locally Advanced or Metastatic Triple-negative Breast Cancer | Phase 3 | Not yet recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 356 | 2026-05-01 | 2026-04-30 |
| A Phase I Study of 9MW4113 Injection Versus Dupixent® 9MW4113 injection, Dupilumab - Healthy Participants | Phase 1 | Active not recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 208 | 2026-04-22 | 2026-08-27 |
| A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors 7MW3711, JS207, Cisplatin - Solid Tumor | Phase 1 / Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 280 | 2026-02-11 | 2026-03-12 |
| First-in-human Study of 7MW4911 in GI Cancer 7MW4911 - GI Cancers | Phase 1 / Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 200 | 2026-01-13 | 2026-08-21 |
| A Phase II Study of 9MW3811 in Patients With Pathological Scar 9MW3811 Injection, Placebo - Scar | Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 30 | 2025-12-29 | 2026-05-08 |
| First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors 7MW4911 - Solid Tumors | Phase 1 / Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 200 | 2025-11-12 | 2025-12-29 |
| A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs bulumtatug fuvedotin - Triple Negative Breast Cancer | Phase 1 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 52 | 2025-08-11 | 2026-03-17 |
| 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer 9MW2821, Toripalimab Injection - Urothelial Carcinoma | Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 90 | 2025-08-01 | 2026-01-02 |
| A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD) 9MW1911, Phase II placebo - Chronic Obstructive Pulmonary Disease COPD | Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 360 | 2025-07-15 | 2025-12-18 |
| 9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors 9MW2821+other anticancer therapy - Gynecological Malignancies | Phase 1 / Phase 2 | Not yet recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 260 | 2025-04-15 | 2025-04-15 |
| A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors 9MW2821, Other anti-cancer therapy - Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 188 | 2025-04-01 | 2025-04-27 |
| 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma 9MW2821, Toripalimab (JS001 ) - Urothelial Carcinoma, Urothelial Carcinoma Bladder | Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 60 | 2025-01-17 | 2025-03-21 |
| A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia 9MW3011, 9MW3011 placebo - Beta-Thalassemia | Phase 1 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 40 | 2024-12-30 | 2025-01-14 |
| A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis 9MW0311, Prolia® - Postmenopausal Women Osteoporosis | Phase 3 | Completed | Mabwell (Shanghai) Bioscience Co., Ltd. | 280 | 2024-11-16 | 2026-08-07 |
| An Exploratory Study to Evaluate the Tolerability and Safety of MWAV201 in Subjects With Wilson Disease MWAV201 - Wilson Disease | Not applicable | Active not recruiting | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 9 | 2024-10-28 | 2026-08-12 |
| A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer 9MW2821, Chemotherapy - Cervical Cancer | Phase 3 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 420 | 2024-09-10 | 2024-11-22 |
| 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer 9MW2821, Toripalimab, Gemcitabine - Urothelial Carcinoma | Phase 3 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 460 | 2024-08-22 | 2024-09-19 |
| A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer 9MW2821, PD-1 inhibitior - Triple-Negative Breast Cancer | Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 160 | 2024-07-26 | 2025-01-10 |
| A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera 9MW3011 - Polycythemia Vera | Phase 1 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 108 | 2024-03-21 | 2025-05-11 |
Showing 20 of 54. Sign in to see all of them.
Carcinoma, Transitional Cell (3) · Pulmonary Disease, Chronic Obstructive (3) · Triple Negative Breast Neoplasms (3) · Asthma (2) · COVID-19 (2) · Dermatitis, Atopic (2) · Neoplasms (2) · Osteoporosis, Postmenopausal (2) · Bone Neoplasms (1) · Cellulitis (1) · Cicatrix (1) · Genital Neoplasms, Female (1) · Hepatolenticular Degeneration (1) · Idiopathic Pulmonary Fibrosis (1) · Leukemia, Myeloid, Acute (1)
Denosumab (4) · toripalimab (4) · Drug Therapy (3) · Infusions, Intravenous (3) · Injections (3) · Carboplatin (2) · Cisplatin (2) · aflibercept (2) · Docetaxel (1) · Gemcitabine (1) · Linezolid (1) · Ranibizumab (1) · dupilumab (1) · pegylated granulocyte colony-stimulating factor (1) · spartalizumab (1)
China (47) · United States (2) · Australia (1)
Feng Wang (1) · Hanmei Lou, Professor (1) · Hu Zhou, Ph.D (1) · Jian Zhang (1) · Jian Zhang, Professor (1) · Jian-Gao Fan, doctor (1) · Saijuan Chen, Doctor (1) · Suxia Luo, professor (1) · Wang Shuhai, Ph.D (1) · Weili Zhao, Doctor (1) · Zhang Jian, Professor (1)
PMID 40288679, PMID 34346827, PMID 34473343, PMID 36892190, PMID 37196158, PMID 38329745, PMID 38752402